Cite
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
MLA
Papp, Kim A., et al. “Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.” BioDrugs, vol. 38, no. 1, Jan. 2024, pp. 121–31. EBSCOhost, https://doi.org/10.1007/s40259-023-00630-5.
APA
Papp, K. A., Lebwohl, M. G., Thaçi, D., Jaworski, J., Kwiek, B., Trefler, J., Dudek, A., Szepietowski, J. C., Reznichenko, N., Narbutt, J., Baran, W., Kolinek, J., Daniluk, S., Bartnicka-Maslowska, K., Reich, A., Andrashko, Y., Kim, S., Bae, Y., Jeon, D., & Jung, J. (2024). Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. BioDrugs, 38(1), 121–131. https://doi.org/10.1007/s40259-023-00630-5
Chicago
Papp, Kim A., Mark G. Lebwohl, Diamant Thaçi, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, et al. 2024. “Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.” BioDrugs 38 (1): 121–31. doi:10.1007/s40259-023-00630-5.